Business
Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.
About this update from Merck & Company, Inc.
[{"type":"text","content":"KIRKLAND, QC, Nov. 20, 2025 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.","length":431,"tagName":"p"},{"type":"image","alt":"Merck Logo (PRNewsfoto/Merck)","displaySize":"","headline":null,"caption":"Merck Logo (PRNewsfoto/Merck)","className":"","disableSlideshowImg":false,"size":{"original":{"width":148,"height":44,"url":"https://media.zenfs.com/en/cnwgroup.com/a31c818593c897369fcfa7d3a78ada87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WPGiatRLHK00PDoDVoPplg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/cnwgroup.com/a31c818593c897369fcfa7d3a78ada87","width":148,"height":44}},"href":"https://mma.prnewswire.com/media/2814415/Merck_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"WINREVAIR® is indicated in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.","length":213,"tagName":"p"},{"type":"text","content":""Pulmonary arterial hypertension is a life-limiting disease that affects patients' ability to work, engage in daily activities, and maintain independence. Ensuring broad and equitable access to innovative therapies like WINREVAIR® is essential," said Jamie Myrah, Executive Director at Pulmonary Hypertension Association of Canada.","length":345,"tagName":"p"},{"type":"text","content":""Having additional therapeutic options that target different pathways is important for clinicians as we tailor treatment plans to individual patient needs with the aim of helping to improve their symptoms, function, quality of life, and overall outcomes," said Dr. Jason Weatherald, pulmonologist at the University of Alberta. "Completion of this negotiation is a meaningful step toward improving greater access to therapies with demonstrated benefits for patients living with PAH."","length":502,"tagName":"p"},{"type":"text","content":"The next step involves prov...